PMID- 2529779
OWN - NLM
STAT- MEDLINE
DCOM- 19891117
LR  - 20171213
IS  - 0002-9513 (Print)
IS  - 0002-9513 (Linking)
VI  - 257
IP  - 4 Pt 2
DP  - 1989 Oct
TI  - Atrial natriuretic peptide reverses angiotensin-induced venoconstriction in dogs.
PG  - H1062-7
AB  - To determine whether atrial natriuretic peptide (ANP) can reverse angiotensin 
      (ANG II)-induced venoconstriction, ANP was infused (0.3 micrograms.kg-1.min-1) in 
      the presence of ANG II-induced hypertension in six ganglion-blocked dogs. ANG II 
      was initially administered to increase mean arterial blood pressure (MAP) 50% 
      above control. ANG II did not change heart rate or left ventricular rate of 
      pressure development (LV dP/dt) but increased total peripheral vascular 
      resistance (TPVR) and left ventricular end-diastolic pressure (LVEDP). Mean 
      circulatory filling pressure (MCFP) increased, whereas cardiac output and venous 
      compliance decreased. Unstressed vascular volume did not change, but central 
      blood volume increased. ANP infusion during ANG II-induced hypertension resulted 
      in a decrease in MAP, but TPVR did not change. There were no changes in heart 
      rate or LV dP/dt. ANP decreased cardiac output further. LVEDP returned to base 
      line with ANP. ANP also decreased MCFP and normalized venous compliance. There 
      was no significant change in total blood volume, but central blood volume 
      decreased. In summary, ANP can reverse the venoconstriction but not the arterial 
      vasoconstriction produced by ANG II. The decrease in MAP was due to a decrease in 
      cardiac output that resulted from venodilatation and aggravation of the 
      preload-afterload mismatch produced by ANG II alone. Because TPVR did not change 
      when MAP fell, we conclude that the interaction between ANG II and ANP occurs 
      primarily in the venous circulation.
FAU - Lee, R W
AU  - Lee RW
AD  - Department of Internal Medicine, Tucson Veterans Administration Medical Center, 
      Arizona 85723.
FAU - Gay, R G
AU  - Gay RG
FAU - Goldman, S
AU  - Goldman S
LA  - eng
GR  - HL-20984/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Physiol
JT  - The American journal of physiology
JID - 0370511
RN  - 11128-99-7 (Angiotensin II)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
SB  - IM
MH  - Angiotensin II/*pharmacology
MH  - Animals
MH  - Atrial Natriuretic Factor/*pharmacology
MH  - Blood Pressure/drug effects
MH  - Cardiac Output/drug effects
MH  - Dogs
MH  - Heart Rate/drug effects
MH  - Hemodynamics/*drug effects
MH  - Reference Values
MH  - Vascular Resistance/drug effects
MH  - Vasoconstriction/*drug effects
MH  - Veins/drug effects/physiology
EDAT- 1989/10/01 00:00
MHDA- 1989/10/01 00:01
CRDT- 1989/10/01 00:00
PHST- 1989/10/01 00:00 [pubmed]
PHST- 1989/10/01 00:01 [medline]
PHST- 1989/10/01 00:00 [entrez]
AID - 10.1152/ajpheart.1989.257.4.H1062 [doi]
PST - ppublish
SO  - Am J Physiol. 1989 Oct;257(4 Pt 2):H1062-7. doi: 
      10.1152/ajpheart.1989.257.4.H1062.